News
DGAP-News: Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
DGAP-News: Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
DGAP-News: MicroVision Announces Timing Change of Webcast on January 5, 2022
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
EQS-News: Relief Therapeutics to Participate in Virtual Investor Conferences in January
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
EQS-Adhoc: Relief Reports that its U.S. Collaboration Partner has Announced the Filing of a Provisional Patent Application for Stable Compositions of Aviptadil Suitable for Human Use
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
DGAP-Adhoc: Eckert & Ziegler kauft argentinischen SPECT-Spezialisten
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Relief Therapeutics Announces Notice of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding SA
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals Announces Hiring of Head of Investor Relations and Senior Leadership Change
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Cosmo Pharmaceuticals gibt die Einstellung einer Head of Investor Relations und einen Wechsel im Management-Team bekannt
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports U.S. Collab. Partner Announces Filing Breakthrough Therapy Request for Aviptadil in Pts at Immediate Risk of Death from COVID-19 Despite Treatment w/Remdesivir, Other Approved Therapies
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Relief Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
EQS-Adhoc: Evolva secures additional financing lines to accelerate its growth
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease
DGAP-Adhoc: NanoRepro AG: Änderung Prognose 2021 und Ausblick 2022 mit Dividende
DGAP-Adhoc: NanoRepro AG: Änderung Prognose 2021 und Ausblick 2022 mit Dividende
DGAP-News: NanoRepro AG: Neues Aufsichtsratsmitglied wird gerichtlich bestellt
DGAP-News: NanoRepro AG: Neues Aufsichtsratsmitglied wird gerichtlich bestellt
DGAP-News: MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
DGAP-News: MagForce AG: Enrollment in Stage 2b of Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System successfully underway following IRB approval
DGAP-News: MagForce AG: Rekrutierung in Stufe 2b der pivotalen US-Studie zur fokalen Ablation von Prostatakrebs mit dem NanoTherm Therapiesystem nach IRB-Genehmigung verläuft erfolgreich
DGAP-News: MagForce AG: Rekrutierung in Stufe 2b der pivotalen US-Studie zur fokalen Ablation von Prostatakrebs mit dem NanoTherm Therapiesystem nach IRB-Genehmigung verläuft erfolgreich
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN DIE ABWICKLUNG DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. UND CASSIOPEA S.P.A. VERÖFFENTLICHEN DIE ABWICKLUNG DES ÖFFENTLICHEN UMTAUSCHANGEBOTS FÜR ALLE SICH IM PUBLIKUM BEFINDENDEN AKTIEN DER CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
EQS-Adhoc: COSMO PHARMACEUTICALS N.V. AND CASSIOPEA S.P.A ANNOUNCE SETTLEMENT OF PUBLIC EXCHANGE OFFER FOR ALL PUBLICLY HELD SHARES IN CASSIOPEA S.P.A.
DGAP-News: Sernova kündigt Update des leitenden Prüfarztes zu seiner klinischen Typ-1-Diabetes-Studie am 13. Januar 2022 beim 22. Wintersymposium der American Society of Transplant Surgeons an
DGAP-News: Sernova kündigt Update des leitenden Prüfarztes zu seiner klinischen Typ-1-Diabetes-Studie am 13. Januar 2022 beim 22. Wintersymposium der American Society of Transplant Surgeons an